Sugar Editorial Picks
Jun 20, 2008 -
It's not always your grandmother's cat that is making you miserable. Allergens lurk everywhere and if, like me, you're a sufferer they can make for a miserable Spring, Summer, and Fall. There are a few allergens that affect more of us than others, and Everyday Health has rounded up some of the top allergens and I've picked out a few highlights for the slideshow.
- 0 Comments
Other Search Results
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Prognosis
- Risk Factors
- Symptoms
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Symptoms
- Complications
- Risk Factors
- Diagnosis
- Dietary Factors
- Symptom Management
- Medications
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the FDA approved LIALDA, the first once-daily mesalamine pill for treating mild-to-moderate ulcerative colitis. Other types of mesalamine need to be taken several times a day.
Genetic Research
Scientists have made an important discovery by identifying a gene associated with inflammatory bowel disease.
- 0 Comments
Feb 09, 2009 -
Start a good habit this Winter: flip your mattress. At least twice a year, you should flip your mattress to keep the wear even. This will also help keep your mattress clean.
- 6 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Diagnosis
- Complications
- Risk Factors
- Prevention
- Treatment
- Medications
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Vaccine News:
- On September 28, 2007, the U.S. Food and Drug Administration (FDA) approved a new brand of inactivated influenza ("flu") vaccine, Alfuria, for adults aged 18 years or older. This vaccine is given by injection.
- On September 19, 2007, the FDA approved the use of the live flu vaccine (FluMist) in healthy children as young as 2 years of age.
- 0 Comments
Jan 21, 2009 -
While much of the nation was captivated with yesterday's inauguration, I couldn't help but continue to wonder about the First Dog-to-be, especially now that the family's all moved into the White House. The Obamas are still sticking to their rescue dog preferences, saying that either a Labradoodle or Portuguese Water Dog are top picks because of their daughter's allergies.
Some people consider those breeds to be "hypoallergenic" because of the limited shedding, yet others claim that the main allergen is excreted as sweat and secreted into the saliva making essentially no dog safe.
- 13 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Complications
- Diagnosis
- Prevention
- Treatment for Acute Sinusit...
- Treatment for Chronic Sinus...
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Restriction
In February 2007, the FDA announced that the antibiotic telithromycin (Ketek) should no longer be used for treatment of acute bacterial sinusitis. In June 2006, the FDA reported that several people had died of liver damage after taking this drug. Telithromycin is now only approved for treatment of community-acquired pneumonia.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Symptoms
- Complications
- Risk Factors
- Diagnosis
- Dietary Factors
- Symptom Management
- Medications
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Biologic Drugs
- In February 2007, the FDA approved adalimumab (Humira) for treatment of adult patients with moderate-to-severe Crohn’s disease. Adalimumab and infliximab (Remicade) are now the two biologic drugs approved for Crohn’s disease. Infliximab is approved for treating both adults and children.
- As of August 2007, the FDA was considering approving natalizumab (Tysabri) for moderate-to-severe Crohn’s disease in patients who have not responded to, or cannot tolerate, other therapies.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Risk Factors
- Symptoms
- Complications
- Barrett's Esophagus
- Diagnosis
- Treatment
- Prevention
- Medications
- Surgery
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
New Research
- Obesity and GERD. Increased weight in women is linked to more frequent GERD symptoms, according to the Nurses' Health Study, which included 10,545 female participants. Overweight and obese women were two to three times more likely to have frequent symptoms than women of normal weight.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Symptoms
- Risk Factors
- Complications
- Diagnosis
- Treatment
- Medications
- Other Treatments
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Urinary Tract Infections (UTIs) in the United States
According to Urologic Diseases in America, a report published in 2007 by the U.S. National Institutes of Health:
- UTIs are the most expensive of all urologic diseases, accounting for about $3.5 billion a year in medical costs, including $96.4 million in prescriptions.
- Over 60% of women will experience a UTI at least once in their lifetime. At least a third of women experience a UTI by the time they are 24 years old.
- Only 20% of UTIs occur in men.
- 0 Comments